Recipharm AB (RECI B):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Recipharm AB (RECI B) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C9777)・商品コード:DATA904C9777
・発行会社(調査会社):GlobalData
・発行日:2018年11月
・ページ数:86
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,750見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Recipharm AB (Recipharm) is a contract development and manufacturing organization (CDMO) that offers manufacturing, and development and technology services. The organization’s manufacturing segment provides contract manufacturing of pharmaceuticals such as semi-solids, and oral liquids, solid dose, sterile products, besides clinical trial materials including APIs and other drugs. Recipharm’s development and technology segment offers raw material supply, formulation development and development of validated analytical methods, and among others. The organization operates in the UK, Germany, Spain, Italy, Sweden, France, and others. Recipharm is headquartered in Stockholm, Sweden.

Recipharm AB (RECI B) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Recipharm AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Recipharm AB, Medical Devices Deals, 2012 to YTD 2018 12
Recipharm AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Recipharm AB, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
Recipharm Acquires CMO Business from Sanofi for USD60.2 Million 15
Recipharm Acquires Manufacturing Facility from Roche 17
Recipharm Acquires Development and Manufacturing Facility from Flamel for USD13.2 Million 18
Partnerships 20
Kancera and Recipharm Enter into Partnership 20
Klaria Pharma Partners with Recipharm and Clinical Trial Consultants 21
Recipharm Enters into Agreement with Follicum 22
Recipharm Enters into Agreement with Synthonics 23
Kemwell Biopharma Enters into Co-Development Agreement for Monoclonal Antibody Therapeutics 24
Recipharm Enters Into Co-Promotion Agreement With Synthonics 25
Licensing Agreements 26
Recipharm Enters into Licensing Agreement with Altus Formulation 26
Alitair Pharma And Edmond Pharma Enter Into Licensing Agreement For Erdosteine 27
Equity Offering 28
Recipharm Raises USD58.7 Million in Public Offering of Share 28
Recipharm Raises USD99 Million in Rights Offering of Shares 30
Recipharm to Raise USD15.5 Million in Private Placement of Class B Shares 32
Recipharm Raises USD32 Million in Private Placement of Shares 33
Synthonics Raises USD2 Million in Private Placement of Preferred Shares 34
Flamel to Raise USD13.1 Million in Private Placement of Shares 35
Recipharm Announces Underwriters Exercise Of Over-Allotment Option Of IPO For US$131.37 Million 36
Debt Offering 38
Recipharm Raises USD116.4 Million in Private Placement of Bonds 38
Asset Transactions 39
Serb Acquires Rights for ThyroSafe from Recipharm for USD11.1 Million 39
Acquisition 40
Recipharm Acquires Remaining 26% Stake in Nitin Lifesciences for USD43.8 Million 40
Recipharm Acquires Kemwell Biopharma for USD120 Million 41
Recipharm Acquires Kemwell and Cirrus Pharma from Kemwell Biopharma 42
Recipharm Acquires 74% Stake in Nitin Lifesciences for USD101 Million 44
Recipharm Italia Acquires Mitim for USD75 Million 46
Recipharm Acquires Kaysersberg Pharma from Alcon for USD16.6 Million 47
Recipharm Acquires OnTarget Chemistry for USD1.8 Million 48
Recipharm Acquires Lusomedicameta Sociedade for USD135 Million 49
Recipharm Acquires Corvette Pharma Services from LBO Italia Investimenti for USD160 Million 50
Kemwell Biopharma Acquires Cirrus Pharma 51
Recipharm AB – Key Competitors 52
Recipharm AB – Key Employees 53
Recipharm AB – Locations And Subsidiaries 55
Head Office 55
Other Locations & Subsidiaries 55
Recent Developments 58
Strategy And Business Planning 58
May 24, 2018: Recipharm invests in Brexit preparations 58
Nov 09, 2017: Recipharm to end operations in two facilities in Sweden 59
Apr 24, 2017: Recipharm opens new GMP suite for clinical trial material 60
Financial Announcements 61
Jul 25, 2018: Recipharm publishes its interim report January-June 2018 61
Feb 22, 2018: Recipharm Reports Fourth Quarter And Full Year 2017 62
Nov 09, 2017: Recipharm: Interim report January – September 2017 64
Jul 25, 2017: Recipharm: Interim report January – June 2017 66
Apr 27, 2017: Recipharm: Interim report January-March 2017 67
Feb 23, 2017: Recipharm: Full Year report January – December 2016 68
Corporate Communications 72
Oct 03, 2018: Recipharm names Tobias Hagglov as Chief Financial Officer 72
May 09, 2018: Recipharm appoints new Chief Financial Officer 73
Feb 26, 2018: Recipharm: Chief Financial Officer to leave Recipharm 74
Feb 14, 2018: Recipharm Appoints President Development Services to Drive End to End Offering 75
Apr 11, 2017: Recipharm appoints Henrik Stenqvist as new Chief Financial Officer 76
Legal and Regulatory 77
Oct 25, 2018: Manufacturing licence restriction at Recipharm, Ashton-u-Lyne, UK facility 77
Sep 13, 2018: Recipharm connects to European Hub for serialisation compliance 78
Product News 79
Oct 09, 2018: Recipharm releases first serialised products to Europe 79
Other Significant Developments 80
Oct 19, 2018: Recipharm continues manufacturing operations in Hoganas, Sweden 80
Jul 02, 2018: Recipharm launches standalone serialisation service 81
Mar 14, 2018: Recipharm completes Blow-fill-seal expansion at Kaysersberg facility 82
Nov 27, 2017: Recipharm equips a further three facilities for US serialisation 83
Oct 23, 2017: Recipharm equips Lisbon facility for US and European serialisation 84
Apr 21, 2017: Recipharm delivers first serialised batch to Saudi Arabia 85
Appendix 86
Methodology 86
About GlobalData 86
Contact Us 86
Disclaimer 86

List of Tables
Recipharm AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Recipharm AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Recipharm AB, Deals By Therapy Area, 2012 to YTD 2018 10
Recipharm AB, Medical Devices Deals, 2012 to YTD 2018 12
Recipharm AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Recipharm Acquires CMO Business from Sanofi for USD60.2 Million 15
Recipharm Acquires Manufacturing Facility from Roche 17
Recipharm Acquires Development and Manufacturing Facility from Flamel for USD13.2 Million 18
Kancera and Recipharm Enter into Partnership 20
Klaria Pharma Partners with Recipharm and Clinical Trial Consultants 21
Recipharm Enters into Agreement with Follicum 22
Recipharm Enters into Agreement with Synthonics 23
Kemwell Biopharma Enters into Co-Development Agreement for Monoclonal Antibody Therapeutics 24
Recipharm Enters Into Co-Promotion Agreement With Synthonics 25
Recipharm Enters into Licensing Agreement with Altus Formulation 26
Alitair Pharma And Edmond Pharma Enter Into Licensing Agreement For Erdosteine 27
Recipharm Raises USD58.7 Million in Public Offering of Share 28
Recipharm Raises USD99 Million in Rights Offering of Shares 30
Recipharm to Raise USD15.5 Million in Private Placement of Class B Shares 32
Recipharm Raises USD32 Million in Private Placement of Shares 33
Synthonics Raises USD2 Million in Private Placement of Preferred Shares 34
Flamel to Raise USD13.1 Million in Private Placement of Shares 35
Recipharm Announces Underwriters Exercise Of Over-Allotment Option Of IPO For US$131.37 Million 36
Recipharm Raises USD116.4 Million in Private Placement of Bonds 38
Serb Acquires Rights for ThyroSafe from Recipharm for USD11.1 Million 39
Recipharm Acquires Remaining 26% Stake in Nitin Lifesciences for USD43.8 Million 40
Recipharm Acquires Kemwell Biopharma for USD120 Million 41
Recipharm Acquires Kemwell and Cirrus Pharma from Kemwell Biopharma 42
Recipharm Acquires 74% Stake in Nitin Lifesciences for USD101 Million 44
Recipharm Italia Acquires Mitim for USD75 Million 46
Recipharm Acquires Kaysersberg Pharma from Alcon for USD16.6 Million 47
Recipharm Acquires OnTarget Chemistry for USD1.8 Million 48
Recipharm Acquires Lusomedicameta Sociedade for USD135 Million 49
Recipharm Acquires Corvette Pharma Services from LBO Italia Investimenti for USD160 Million 50
Kemwell Biopharma Acquires Cirrus Pharma 51
Recipharm AB, Key Competitors 52
Recipharm AB, Key Employees 53
Recipharm AB, Other Locations 55
Recipharm AB, Subsidiaries 55

List of Figures
Recipharm AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Recipharm AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Recipharm AB, Medical Devices Deals, 2012 to YTD 2018 12

★調査レポート[Recipharm AB (RECI B):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C9777)販売に関する免責事項を必ずご確認ください。
★調査レポート[Recipharm AB (RECI B):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆